Últimos Artículos de Lancet Diabetes & Endocrinology
- [Series] Management of menopause: a view towards prevention
- [Editorial] Menopause: a turning point for women's health
- [Series] Menopause: a cardiometabolic transition
- [In Focus] Hot topics on insulin access: the issue of thermostability
- [Comment] Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer
- [Country Focus] Singapore's “War on Diabetes”
- [Articles] Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
- [Comment] SURPASSing the current dogma: is our framework shifting?
- [Comment] Add-on value of tirzepatide versus semaglutide
- [Articles] Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
- [Comment] Tirzepatide adds hepatoprotection to its armoury
- [Articles] Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
- [Correspondence] Methodological considerations in D-health cancer mortality results – Authors' reply
- [Correspondence] Methodological considerations in D-health cancer mortality results
- [Comment] The ABC targets of diabetes in India
- [Articles] Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study
- [Comment] Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care
- [Editorial] Long COVID: the elephant in the room
- [In Focus] War in Ukraine ups demand for iodine pills
- [Comment] Targeting PCSK9 inhibitors to those who will benefit most